TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD
To evaluate the feasibility and safety of TLI/ATG conditioning for allogeneic HCT for elderly patients with advanced stage MDS and MPD.
Myeloproliferative Disorders|Blood Cancer|Myelodysplastic Syndromes
PROCEDURE: Total Lymphoid Irradiation (TLI)|PROCEDURE: Anti-Thymocyte Globulin as Conditioning (ATG)
To improve survival outcome for selected patients with advanced stages of MDS and MPD with non-myeloablative allogeneic HCT from related and unrelated donors., 7/15/2017|To evaluate the feasibility and safety of TLI/ATG conditioning for allogeneic HCT for elderly patients or those with co-morbid conditions that preclude myeloablative transplantation for advanced stage MDS and MPD., 7/15/2017
To evaluate myeloid and platelet engraftment., 7/15/2017|To evaluate the incidence of acute and chronic GVHD., 7/15/2017|To evaluate the rate of primary and secondary graft failure., 7/15/2017|To evaluate the rate of relapse, survival and event-free survival., 7/15/2017|To evaluate if DLI can be used safely in patients with mixed chimerism., 7/15/2017
Total Lymphoid Irradiation and Anti-Thymocyte Globulin as Conditioning for Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for the Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (except CML). To evaluate the feasibility and safety of TLI/ATG conditioning for allogeneic HCT for elderly patients or those with co-morbid conditions that preclude myeloablative transplantation for advanced stage MDS and MPD.